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INTRODUCTION 
The most common cause of mortality in patients with type 2 diabetes 
mellitus (T2DM) are cardiovascular diseases.[1]  The Multiple Risk Factor 
Intervention Trial (MRFIT) and the Framingham study showed a 2–3 fold 
increase in the risk  of atherosclerotic disease in patients with T2DM.[2,3] 
Similarly,  progression of atherosclerosis in persons with T2DM shown in 
Insulin Resistance Atherosclerotic Study.[4] The Cholesterol Lowering 
Atherosclerosis Study (CLAS) has shown the heightened risk of 
atherogenic profile associated with Diabetes Mellitus patients.[5] 
World Health Organization has defined stroke as “the rapidly 
developing clinical signs of focal/global disturbances of cerebral function, 
with symptoms lasting 24 hours or longer or leading to death with no 
apparent cause other than of vascular origin”.[6]  
Two types of stroke are: (i) ischemic 80–85% and (ii) hemorrhagic 
15–20%.[7] Ischemic strokes are further divided into (a) embolic (b) 
thrombotic and (c) secondary to systemic hypoperfusion. Apart from other 
risk factors like  smoking, hypertension, hyperlipidemia, family history, 
etc., diabetes mellitus is a well-recognized risk factor of  cerebro vascular 
,coronary, peripheral vascular diseases.[7,8,9] 
Carotid intima media thickness (CIMT) is widely used as a marker 
of atherosclerosis, considered to be an important pathogenic mechanism of 
Macrovascular diseases.[10]  
 Carotid artery intima-media thickness by B mode ultrasound is a 
simple, non-invasive and reproducible imaging parameter to evaluate 
atherosclerotic vascular diseases. 
Recently, considerable attention has been directed at  the carotid 
arteries intima media thickness as an early marker of atherosclerotic 
disease and as a means of showing the effectiveness of medical therapies 
in treating atherosclerosis. Non-invasive techniques such as B-mode 
ultrasound can directly assess the carotid intima-media thickness (IMT), 
which corresponds to the histologic intima and media thickness. 
Ultrasound imaging of carotid vessels can provide information on 
Carotid Intima Medial Thickness (CIMT),wall diameter, plaque presence 
and type, and calcification, offers the ability to examine pre-symptomatic 
lesions, assess atherosclerotic burden and hence the risk of macrovascular 
events. 
Such non-invasive screening procedures are valuable in identifying 
diabetic patients at risk for macro vascular complications. In clinical 
settings, this can potentially lead to early interventions and treatment. 
 The carotid arteries are among the vessels that are prone to 
developing overt atherosclerotic lesions in the presence of risk factors such 
as smoking, diabetes, hypertension,   and dyslipedemia.10,11 
Diabetes mellitus patients suffer unduly from premature and severe 
atherosclerosis. The Framingham study  shown that “ diabetic individuals 
have higher serum concentrations of lipids and  hypertension, obesity, and 
thus  they are more prone to metabolic syndrome and it’s sequelae, namely 
coronary artery disease (CAD), cerebrovascular disease and vascular 
atherosclerosis” .12 
In type 2 DM, carotid intimal thickness is significantly more than in 
corresponding healthy age and sex matched non diabetic subjects. 
Hence measurement of carotid intimal thickness using high 
resolution B mode ultrasonography which is non- invasive well validated 
method is used to assess early manifestations of atherosclerosis . 
 
 
                      REVIEW OF LITERATURE 
EPIDEMIOLOGY OF TYPE 2 DIABETES: 
  The global burden due to diabetes is mostly contributed by type 2 
diabetes which constitutes 80% to 95% of the total diabetic population. 
Diabetes mellitus is the most common metabolic disease which is 
prevalent in every part of the world and is a major public health challenge 
of the twenty-first century. The explosive increase in the prevalence of 
diabetes seen in the last three decades poses huge clinical and economic 
burden in many countries. The estimates by the International Diabetes 
Federation (IDF) show that 285 million adults (20 to 79 years) are affected 
by the disorder in 2010. Epidemiological trends indicate that without 
proper control and prevention, its prevalence will increase further to 438 
million in 2030. This accounts for a global increase by 54%, i.e. a rise from 
a prevalence of 6.6% to 7.8% in 20 years. Nearly 70% of the people with 
diabetes live in developing countries; the largest numbers are in the Indian 
subcontinent and China. Nauru has the highest prevalence of diabetes 
(30.9%) and will continue to be so in 2030 (33.4%). Many Arab countries, 
Tonga, and Malaysia are among the top ten countries having high 
percentages of people with diabetes. There is little gender difference in the 
distribution in the number affected with  
 
diabetes. The largest numbers with diabetes are in the 40 to 59 age groups 
(132 million, in 2010) which is expected to rise further. By 2030, there will 
be more diabetic people in the 60 to 79 age groups (196 millions).(25,26) 
DIABETES PREVALENCE IN INDIA 
 Diabetes prevalence in India in 1970’s was 2.3% in urban and 1.5% 
in rural areas, as shown by the multi-centric study by the Indian Council 
of Medical Research (ICMR). In 2000s, the prevalence has risen to 12% 
to 19% in urban areas and to 4% to 9% in rural areas. Though, the studies 
are not strictly comparable due to methodological differences,  the rising 
trend in prevalence of diabetes in urban and rural areas in India, is evident.  
National studies or population based studies on diabetic complications are 
sparse in India.(26,27) A few population based studies indicate the 
prevalence of retinopathy to be 18% to 27.0% and overt nephropathy to be 
about 2.2% with a large percentage (27%) having microalbuminuria. 
Peripheral vascular disease is prevalent in 6.3%, peripheral neuropathy in 
26%, and coronary artery disease (CAD) is detected in 21%. The major 
contributory factors for the high prevalence of the complications are; 
delayed diagnosis of diabetes, inadequate control of glycaemia, 
hypertension, and lack of awareness about the disease among majority of 
the public. 
 ECONOMIC BURDEN DUE TO DIABETES 
  Diabetes care cost high and is escalating world wide. It is estimated 
by the WHO that the global expenditure for diabetes care would increase 
from 234 Billions in 2007 to 411 Billions in the next 20 years. The WHO 
estimate is based on “ lost productivity due to diabetes, heart diseases, and 
stroke together show that over the next 10 years, lost national income in 
billions of USD will amount to 555.7 in China, 303.2 in Russian 
Federation, 336.6 in India, 49.2 in Brazil, and 2.5 in Tanzania”.(26,27) 
 A study in India showed that the median expenditure had risen from 
INR 4,200 to INR 9,000 between 1998 to 2005. The indirect cost is much 
higher than the direct cost and is more difficult to assess. The proportion 
of annual income spent on health care is about 25% to 30% by the people. 
The cost increases many fold when diabetic complications are present. 
PREVENTION OF DIABETES  
  Several systematic long-term prospective studies from different 
parts of the world have shown that type 2 diabetes is largely preventable. 
Although the genetic factors cannot be modified, its interaction with the 
diabetogenic environmental factors can be prevented by modifying 
obesity, diet, and physical  
 activity. Indian Diabetes Prevention Programmes (IDPP-1 and IDPP-2) 
have shown that by improving physical activity and by using healthy diet, 
incidence of diabetes can be significantly reduced with a relative risk 
reduction of ~ 30%, in persons with IGT. Metformin in small doses was 
also found to be effective in primary prevention of diabetes. Lifestyle 
changes due to urbanisation and modernisation have caused unhealthy diet 
habits, lack of physical activity, and increased stress leading to overweight 
or obesity with higher levels of insulin resistance. India and many other 
developing countries are going through this scenario and as a result, we 
notice more of chronic metabolic disorders than communicable diseases 
posing increasing challenge to the national health.(29) 
Type 2 diabetes mellitus patients are at 2- to 6-fold higher risk for 
macrovascular disease than persons without diabetes.  Moreover, 
atherosclerosis is thought to begin in the early prediabetic stage and to 
progress silently for years before clinical events such as acute coronary 
syndromes, cerebrovascular accidents or peripheral vascular disease occur. 
So, The above facts compels strongly for detecting early changes of 
atherosclerosis and starting intervention earlier in type 2 diabetic 
patients.(15). 
GENETIC FACTORS  IN DIABETES: 
Type 2 diabetes is a polygenic disorder, caused by a cluster of 
susceptibility genes. The classic method of candidate gene identification 
has been unsuccessful in unravelling these genes. The problem has also 
been approached by studying the functional candidate genes, tracing back 
the functional or biochemical abnormality to the genetic abnormality. 
Further, linkage analysis and micro satellite genotyping technique 
followed by positional cloning has been tried with limited success. (38) 
Although the prevalence of these varieties of diabetes would vary in 
various ethnic groups, it is estimated that they do not make more than about 
5% to 10% of young-age diabetes. Some rare genetic abnormalities 
described are insulin gene abnormality which produces an abnormal 
insulin or a convertase deficiency which impairs the conversion of 
proinsulin to insulin. Abnormalities of insulin receptor are rare. They 
produce syndromes of extreme insulin resistance (type A insulin 
resistance, Leprechaunism, Rabson-Mendenhall syndrome; Table 1). If all 
these anomalies are put together, they may not make more than 1% of all 
type 2 diabetes. The search for genetic abnormalities in the common form 
of type 2 diabetes has been very intense but not very fruitful.  Most 
susceptibility genes described increased the hazard ratio in diabetics versus 
the normal population only marginally.(39,40) 
Of a variety of candidate genes, calpain-10, Kir 6.2, peroxisome 
proliferator activated receptor-γ, hepatocyte nuclear factor-4α gene and 
transcription factor 7-like 2 gene are important. Many of these genes 
predispose to obesity, thus leading to diabetes. However, an interesting 
gene, ENPP-1 K121Q causes insulin resistance in the non-obese Asian 
Indians and is one of  the susceptibility genes in this population. 
ENVIRONMENTAL FACTORS 
Physical inactivity and excessive caloric intake are well recognised 
environmental factors producing type 2 diabetes. These factors can 
produce the disease independently in a genetically susceptible person, but 
usually work via production of obesity. Obesity and type 2 diabetes are 
inextricably interrelated. They further coexist in the form of metabolic 
syndrome, together with other anomalies like hypertension, high 
triglycerides, and low HDL-cholesterol. It is estimated that 25% to 30% of 
the population in India and elsewhere suffers from the metabolic 
syndrome. In the shadow of a global spurt of obesity, type 2 diabetes is 
emerging as an epidemic. Obesity results from the interaction of multiple 
susceptibility genes with environmental factors. By various estimates, 
aetiologically hereditary factors account for 50% to 70% of the obesity. 
Obesity is characterised by insulin resistance, an important feature of type 
2diabetes. 
  
 
 
 
 
 
 
 
GENE-ENVIRONMENT INTERACTIONS  
The mechanism of interaction of gene and environment is a very 
complex issue. The environmental factors interact by altering the 
expression of genes. There is also a gene-gene interaction. Intrauterine 
environment also may influence the subsequent development of many non-
communicable diseases like diabetes, obesity, and hypertension. Low birth 
weight, presumably due to poor maternal nutrition leads to development of 
insulin resistance in childhood and adult life. This is further exacerbated 
by over-nutrition in the post-natal period.(39,40) Epigenetic phenomenon, 
where unchanged DNA sequence can lead to altered phenotype, probably 
due to enhanced or suppressed expression of certain genes that may be 
responsible for obesity and diabetes Environmental factors may operate 
through epigenesis. 
BIOCHEMICAL PERTURBATIONS  
The biochemical perturbations in type 2 diabetes were described 
earlier than the genetic factors. Of these, the most well known 
abnormalities are of peripheral and hepatic insulin resistance, and impaired 
β-cell function. Peripheral and Hepatic Insulin Resistance With the advent 
of radioimmunoassay, massive data on serum insulin levels in obesity and 
diabetes became available.  
Hyperinsulinaemia was described first in obesity and later in type 2 
diabetes, including type 2 normal weight diabetic. Thus, the concept of 
insulin resistance emerged. In spite of high insulin levels, there is poor 
glucose utilisation and insulin inaction in the muscle, adipose tissue, and 
liver.  
In type 2 diabetes, adipose tissue in general and visceral fat in 
particular, exhibits a decreased inhibition of lipolysis and increased 
lipoprotein lipase activity, both resulting in a heightened flux of fatty acids 
in the liver and other tissues. High fatty acids levels are known to inhibit 
glucose utilisation, as demonstrated by Randle (glucose-fatty acid 
cycle).(40,41) In type 2 diabetes and obesity, the adipose tissue also 
expresses increased amounts of 11β-hydroxysteroid dehydrogenase type 1 
(11 β HSD-1), leading to increased cortisol levels and increased lipolysis 
locally. Adipose tissue is known to cause insulin resistance by secreting 
TNF-α and interleukins. Of the multiple adipose tissue hormones, resistin 
is responsible for insulin resistance, while adiponectin and leptin 
ameliorate insulin resistance. Although leptin levels are high in type 2 
diabetes, there is also a state of leptin resistance. These biochemical 
abnormalities are accentuated in the abdominal adipose tissue, which is 
known to be abundant in type 2 diabetes.  
Interestingly, Asian Indians have increased adiposity even at a 
relatively low BMI, which may be one of the reasons for the increased type 
2 diabetes. For this reason, the BMI above 23 kg/m2 is also considered 
overweight in the Asian Indians, unlike the cut-off point of 25 kg/m2 in the 
Caucasians. The skeletal muscle glucose utilisation is impaired to a greater 
degree than adipose tissue in type 2 diabetes (Figure 1). In the post-prandial 
state, the glucose is primarily deposited as glycogen in the muscle. 
Hyperinsulinaemic-euglycaemic clamp studies have shown that the non-
oxidative glucose disposal, like that in hexose monophosphate (HMP) 
shunt is severely impaired in type 2 diabetes and other insulin resistant 
states. The cause of this resistance is a high free fatty acid (FFA) 
concentration in the myocytes, as demonstrated in several studies by using 
a nuclear-magnetic resonance imaging. This would limit the glycogen 
synthesis through the HMP shunt. Recently, a defect in glucose transport 
has been described in the milieu of high fatty acids.(41,42)  In insulin 
resistant state, fatty acid oxidation or re-esterification leading to 
triglyceride synthesis is also impaired, thus leading to high levels of intra-
myocellular FFA. On exercise, many of the abnormalities, including the 
diminished amount of glycogen synthase gets corrected, thus improving 
insulin sensitivity. Exercise increases glucose transporter activity, 
improves capillary density, increases mitochondrial mass, and increases 
type 2 A muscle fibres which are involved in the glycolytic process. 
           The hepatic insulin resistance leads to enhanced gluconeogenesis 
and glycogenolysis. Thus, increased hepatic glucose production is a 
hallmark of uncontrolled diabetes. Type 2 diabetes is often associated with 
a fatty liver, with or without elevated liver enzymes and evidence of hepatic 
necrosis. 
 It is also a manifestation of hepatic insulin resistance and is often 
reversed by weight loss and the use of insulin sensitisers. The molecular 
mechanism of insulin resistance has been a subject of intensive studies 
(Figure 2).  
The resistance is very rarely due to an abnormal insulin or insulin 
receptor. Sustained hyperglycaemia produces glucotoxicity, probably by a 
failure to enhance hexosamine pathway, leading to increased glucosamine 
levels. Increased glucosamine levels can produce insulin resistance in 
adipose tissue and skeletal muscle. Sustained hyperinsulinaemia also 
down-regulates the insulin receptor and further aggravates insulin 
resistance.(39,40) The main locus of the resistance appears to reside at the 
post-receptor level. Insulin signalling is initiated by the binding of insulin 
to alpha subunits of the receptors. This initiates a cascade of auto-
phosphorylation and dephosphorylation through the intra-cellular tyrosine 
kinase, insulin receptor substrates (IRS-1, 2, 3, 4) and other signal 
regulatory protein family (Gab-1,Cb-1, CAP, APS).  
The β subunit of insulin receptor has been shown to undergo besides 
tyrosine auto-phosphorylation, a serine-threonine phosphorylation. The 
latter type of phosphorylation increases insulin resistance and impairs 
insulin signal transduction. The insulin signal is terminated by 
dephosphorylation of the β subunit of receptor by tyrosine phosphatases, 
the activities of which is increased in insulin resistant states.(43) 
 
Fig: Molecular mechanisms of insulin resistance. 
Following the insulin receptor phosphorylation a number of down 
stream events, including an increase in phosphatidyl inositol-3 kinase (Pl-
3 kinase) leads to the translocation of GLUT4. In insulin resistant state, the 
GLUT-4 is not depleted, but its translocation is hampered. The 
glucocorticoid-induced insulin resistance is also associated with a reduced 
insulin stimulated IRS-1 associated Pl-3 kinase. 
Insulin Secretory Defects in Type 2 Diabetes 
In a non-diabetic individual, besides the meal-related insulin 
secretion, there are rapid oscillations in insulin secretion every 8 to 15 min, 
without any glycaemic stimulus. There is also a circadian rhythm occurring 
every 80 to 150 min. Overall, about 18 to 32 units of insulin are secreted 
daily and about 50% is extracted by the liver for local action during its first 
passage. In type 2 diabetes, the rapid meal-related insulin secretion, which 
primarily occurs in about 30 min post-meal and mostly represents the 
preformed insulin, is attenuated. The post-meal response for the 2-hour 
period post-meal appears to be exaggerated but in relation to the high 
glycaemic levels is indeed also impaired.  In obesity and impaired glucose 
tolerance group, absolute amounts of insulin secreted may be 
excessive.(38,39) 
The molecular mechanism of this phenomenon is probably an 
overexpression of hexokinase gene as compared to the glucokinase gene. 
As the former has a low Michaelis constant (Km) for glucose, 
hypersecretion is produced. The circadian rhythm of both types of non-
meal related insulin responses is also altered or attenuated. The β-cell mass 
appears to be slightly reduced at the time of diagnosis of diabetes; however, 
the functional capacity is impaired out of proportion to its mass and hence 
in many studies, a 50 % reduced insulin response has been described at the 
onset of type 2 diabetes. Subsequently, the β cell mass declines further in 
a relentless fashion with increasing insulinopaenia. This is at time 
correlated to fibrillary amylin deposition in the β-cells.(43) 
The genetic factors that determine β cell differentiation, growth and 
apoptosis are being intensively studied at present. The growth factors and 
their biology is yet to be elucidated. It obviously holds the key to a fruitful 
avenue for intervention. However, it is characterised by an early apoptosis 
of β cells. The insulin resistance and β cell failure exist and progress pari 
passu. In early phases there is predominately a resistant state. 
Subsequently, β cell failure dominates the scene. The β-cell is able to 
compensate by increased insulin secretion in the face of rising blood 
glucose, but at about 140 mg/dL of blood glucose the insulin secretion 
levels off and a further rise in blood glucose results in diminishing insulin 
secretion (Figure 3). In about 10% of type 1 diabetics, the β cell failure 
may be due to auto immunity. This is called latent autoimmune diabetes of 
adults (LADA) and aetiologically represents a forme fruste of type 1 
diabetes.(14) 
OTHER PATHOGENETIC MECHANISMS  
Besides the role of β cell, skeletal muscle, adipose tissue, and liver 
in the genesis of type 2 diabetes, a few other important pathogenetic 
mechanisms have been described. The gastrointestinal tract secretes a 
group of important hormones, collectively labelled as incretins. This 
includes two extremely wellknown members: glucagon like peptide (GLP-
1) and glucosedependent insulinotropic peptide (GIP). The former is 
secreted from the L-cells of the ileum and the latter from the K-cells located 
in the proximal small intestine. These hormones account for the enhanced 
insulin secretory response upon ingestion of glucose orally, as compared 
to that obtained by intravenous glucose administration. This has been 
termed the incretin effect. In type 2 diabetes, the incretin effect is blunted, 
which can be corrected by injecting GLP-1 or its longer acting analogue, 
like exenatide or liraglutide. GLP-1 is normally destroyed by a group of 
enzymes called dipeptyl peptidases, of which dipeptyl peptidase-IV 
(DPPIV) is the predominant one. Compounds inhibiting DPP-IV inhibitors 
prolong the effect of endogenous GLP-1 and are being used therapeutically 
at present.(14) 
Although non-suppressibility of glucagon following a meal was 
described in type 2 diabetes almost 4 to 5 decades ago, it gained further 
relevance recently, with the availability of therapeutic tools to correct this 
anomaly. GLP-1 analogues and DPP-IV inhibitors described above correct 
this defect by suppressing glucagon levels post-prandially. Tachy-
alimentation has also been described to aggravate diabetes by exposing the 
body to sudden surge of nutrients. GLP-1 analogues and DPP-IV inhibitors 
are known to retard gastric emptying, thus offering an additional 
mechanism of action.  
The hypothalamic neurons and neurotransmitters have been 
considered in the pathogenesis of type 2 diabetes. There are numerous 
changes described in the neurotransmitter secretion in obesity and type 2 
diabetes. The rapid first phase insulin response is mediated through these 
pathways. It has been demonstrated that the hypothalamic nuclei regulating 
appetite are also insulin resistant. After the ingestion of glucose, the 
elevated plasma insulin levels are unable to exert the inhibitory response 
in these nuclei in obese, insulin resistant individuals. Hence, 
pharmacological manipulation of these neurons by promoting satiety can 
be utilised in type 2 diabetes. More recently, dopamine agonists, like 
bromocriptine have been shown to improve hyperglycaemia in type 2 
diabetes. 
 Another new pathogenetic mechanism described shows 
involvement of kidney in the pathogenesis of type 2 diabetes. Normally 
about 160 g of glucose is filtered in the glomerular filtrate; 90% of it is 
absorbed in the proximal convoluted tubule by a high capacity glucose 
transporter called SGLT2. Remaining 10% of the filtered glucose is 
absorbed in the straight descending part of the proximal tubule by another 
glucose transporter SGLT-1. It has been demonstrated that in type 1 
diabetes the tubular maximum for the glucose absorption is increased. 
Although it is not clear whether the same holds true of type 2 diabetes, the 
levels of SGLT-2 mRNA is four-fold increased in the proximal tubular 
renal cells. This may account for increased glucose resorption and hence, 
hyperglycaemia. Inhibition of SGLT has provided another avenue to treat 
type 2 diabetes.  
In summary, type 2 diabetes originates from a complex interaction 
of genetic and environmental factors, which express themselves in the form 
of myriad biochemical abnormalities. 
ATHEROSCLEROSIS IN DIABETES: 
The increased prevalence of macrovascular disease among diabetic 
subjects prompted research workers to probe into the causes for the 
acclerated atherogenic process of diabetic subjects. Dyslipidemias 
contribute to considerable increased risk of atherosclerosis and consequent 
mortality in diabetes. Dyslipidemias often precedes onset of type 2 DM 
and may persist inspite of adequate control of blood sugar.2. 
HISTORY OF ATHEROSCLEROSIS: 
1449-1519- Leonardo Da Vinci described thickening of tunica of 
blood vessels in aged People. Rokinstansky proposed the Incrustation 
theory for pathogenesis of Atherosclerosis. 
 
1858- Virchow proposed Inhibition Hypothesis for pathogenesis of 
atherosclerosis. 
 
1904- Marchand introduced the term atherosclerosis. 
 
1957 - Robertson modified the Incrustation theory and proposed that 
intimal thickening results from fibrin deposition with subsequent 
organization of fibroblasts and secondary accumulation of lipids. 
 
1960s and 1970s - concepts such as endothelial cell damage and 
injury were described. 
 
1979- Garret et al proposed that monocyte accumulation in sub-
endothelial space was responsible for formation of fatty streak. 
 1985- Davies et al proposed that plaque fissuring with thrombosis as 
the cause of acute coronary syndrome. 
 
1994-George Howard and co-workers concluded that increased 
CIMT at one site is positively associated with thickened walls at other 
carotid sites. 
 
 1997-M.L. Bots and co-workers concluded that common carotid 
intima media thickness and carotid plaques are markers for increased risk 
of stroke, coronary heardisease and death within 12 years(7) 
LIPIDS 
Lipids are organic substances occurring in biologic systems. They 
are esters of fatty acids and are insoluble in water but soluble in organic 
solvents. Lipids are broadly grouped into 
A) Simple lipids -Naturals fats, waxes 
B) Compound lipids-Phospholipids, glycolipids, lipoproteins 
C) Derivatives-Fattys acid, glycerol, sterols. 
 Among naturals fats, triglycerides form the major part of the dietary 
fat intake. Compound lipids are structural lipids. Glycolipids in cell 
membrane , sphingomyelins in nervous system and lipoproteins in blood 
serve as important physiologic functions. sterols are solid alcohol .The 
principle sterol in man is cholesterol. 
Fatty acids are esters of a naturally occuring alcohol like glycerol. 
Fatty acids from animal tissues are usually unbranced and contain an even 
number of carbon atoms. They are classified based on the presence or 
absence of double bond between the carbon atoms. when two or more than 
two double bonds exist they are called poly unsaturated fatty acid.(16) 
 
Functions of lipids: 
1)  Cholesterols are structural components of cell membrane. They are 
precusors of bile acids and steroid hormones 
2)  Triglycerides form the major energy stores of the body. 
3)  Phospholipids are structural constituents of cell membrane. 
LIPID METABOLISM IN DIABETES: 
Insulin is an anabolic hormone which promotes a) esterification of 
fatty acids b) stimulates glucose uptake in peripheral tissues and c) 
conversion of glucose to glycogen. Insulin inhibits the hormone sensitive 
lipase activity in adipose tissue. hence in insulin deficiency there  is 
enhanced mobilisation of fatty acids from adipose tissue. This lipolysis 
results both from insulin lack of and in the setting of associated counter 
hormone excess. Fatty acids and ketone bodies thus formed secondarily 
enhance insulin resistance. adequate level of insulin are necessary for 
triglyceride synthesis and VLDL  secretion. HMG Co A is the rate limiting 
enzyme in cholestrol synthesis. Insulin increases its activity and thus 
regulates hepatic cholesterol synthesis. In addition insulin, affect LDL 
transport kinetics. The fractional catabolic rate of LDL is reduced without 
changes in synthesis in type 2 DM.(16) 
 
 FIG: DEVELOPMENT OF ATHEROSCLEROTIC PLAQUES 
 
Pathologic changes in atherosclerosis process: 
1. Intimal thickening 
2. Fatty streaks 
3. Gelatinous lesions 
4. Atheromatous plaque 
5. Complicated plaques 
 
 
1. Intimal thickening:  
The Initial lesion consists of smooth muscle cells, fibrous tissue and  
collagens, but no lipid. 
2. Fatty streaks: 
These composed of very closely packed foam cells, lipid containing 
elongated smooth muscle cells and some lymphoid cells. Small 
amount of extra cellular lipid, collagen and proteoglycans are also 
seen. They are considered as the precursors of plaques. 
3. Gelatinous lesions: 
These are foci of the increased ground substance in  intima with 
thinned overlying endothelium. They are also considered as the 
precursors of plaques. 
     4. Atheromatous plaques: 
Atheromatous plaque is a fully developed atheromatous lesion.  
4. Complicated plaques:  
Various complications may occur in fully developed lesions. These 
include thrombosis, hemmorhage, calcification, ulceration, and 
aneurysm formation.(12) 
 
  
CHRONIC COMPLICATIONS OF DIABETES MELLITUS: 
 
 
  
Macrovascular complications 
 Coronary artery disease 
 Cerebrovascular disease 
 Peripheral vascular disease 
Microvascular disease 
 Neuropathy 
 Nephropathy 
 Retinopathy 
Mechanisms of Complications: 
1. Endothelial Dysfunction: “ Endothelium which is the innermost 
layer of the blood vessels and in fact the largest organ of the body is the 
initial and common target of all cardiovascular risk factors. The functional 
impairment of the vascular endothelium in response to injury occurs long 
before the development of visible atherosclerosis.  
                  The endothelial cell behaves as a receptor-effective structure 
which senses different physical or chemical stimuli that occur inside the 
vessel and, therefore, modifies the vessel shape or releases the necessary 
products to counteract the effect of the stimulus and maintain homeostasis. 
The endothelium is capable of producing a large variety of different 
molecules including the vasodilators (nitric oxide [NO] and prostacyclin) 
and vasoconstrictors (endothelin-1 and angiotensin II) and nicely balancing 
their effects. When this delicate balance is lost, the conditions are given for 
the endothelium to be invaded by lipids and leucocytes (monocytes and T-
lymphocytes).  The inflammatory response is incited and fatty streaks 
appear – the first step in the formation of the atheromatous plaque which 
may later rupture and set the conditions for thrombogenesis and vascular 
occlusion. Therefore, endothelial dysfunction which is universal in 
diabetes is the starter in the process of atherosclerosis and many other 
factors are the chasers.  
          As a result of this, vascular NO synthesis and stability are reduced 
and there is an impairment of endothelium-dependent NO-mediated 
vasodilatation in diabetes. In the presence of endothelial dysfunction the 
powerful vasoconstrictors like endothelin-I and angiotensin-II replace the 
vasodilators, NO and prostacyclin.(14)” 
 
 2. Oxidative Stress : “Oxidative products are produced as a consequence 
of normal aerobic metabolism. These molecules are highly reactive with 
other biological molecules and are referred to as reactive oxygen species 
(ROS). Under normal physiological conditions, ROS production is 
balanced by an efficient system of antioxidants, molecules that are capable 
of neutralising them and, thereby, preventing oxidant damage. In 
pathological states, ROS may be present in relative excess. This shift of 
balance in favour of oxidation termed ‘oxidative stress’ may have 
detrimental effects on cellular and tissue function and the cardiovascular 
risk factors generate oxidative stress. Both type 1 and type 2 diabetic 
patients are under enhanced oxidative stress. Hyperglycaemia causes 
nonenzymatic glycosylation of proteins and phospholipids, thus increasing 
the intracellular oxidative stress. Therefore, advanced glycosylation end 
products (AGEs) formed later in this process are stable and virtually 
irreversible and generate ROS with consequent increased vessel oxidative 
damage and atherogenesis”. 
 
 3. Activation: “ Activation of polyol pathway and diacylglycerol 
(DAG), protein kinase C (PKC) cascade are the other consequences of 
persistent hyperglycaemia (uncontrolled diabetes). Excess of intracellular 
glucose is metabolised by sorbitol pathway; and there is also rise in DAG, 
PKC levels intracellularly consequent to persistent hyperglycaemia. This 
occurs in many tissues including heart, aorta, glomeruli and retina”.  
 
4. Other Factors: “ There are many cardiovascular risk factors in 
diabetes and insulin resistance (IR). These are metabolic and lipid-related 
factors, coagulation and inflammatory factors and vascularrelated factors 
(Table 1). Some of them are primarily related to diabetes while others may 
be found in diabetic as well as non-diabetic individuals. Type 2 diabetes 
and IR typically occur in the setting of metabolic syndrome which also 
includes visceral (abdominal) obesity, hypertension, dyslipidaemia, and 
increased coagulability all of which lead to atherosclerosis (Figure 1). Even 
in this setting of multiple risk factors, type 2 diabetes acts as an 
independent risk factor for the development of ischaemic heart disease 
(IHD), stroke, and death. Among people with type 2 diabetes women may 
be at a higher risk for CHD than men. The prevalence of microvascular 
disease in itself is also a predictor of CHD”.(14). Important steps in the 
initiation and growth of atherosclerotic plaque are:  
1. Endothelial dysfunction and injury  
2. Sub-endothelial monocyte/macrophage accumulation  
3. Lipoprotein infiltration 
4. Smooth muscle cell proliferation 
  
 5. Influence of T lymphocytes and other inflammatory cells and 
protein lipid accumulation in foam cells finally leading to plaque formation 
and adhesion thrombosis.(14) 
 
Hyperglycemia is the most  important  single cause of chronic 
complications in diabetes which has been proved by the diabetes control 
and complications trial (DCCT).Patients with insulin -dependent diabetes 
whose intensive insulin therapy resulted in HbA1c values of 2% lower than 
those receiving conventional insulin therapy, had a 76% lower incidence 
of retinopathy and a 60% reduction in neuropathy. 
UKPDS study is the best evidence to prove that intensive drug 
treatment to lower blood glucose concentration is effective in reducing the 
risk  of long term microvacular complications. This study also proved that 
strict control of blood pressure and lipids is also important in reducing the 
risk of diabetic complications. 
These alterations remain reversible if good control of hyperglycemia 
is achieved. However if persistence of  hyperglycemia and in the presence 
of secondary factors such as hypertension, hyperlipedemia, smoking, 
alcohol, environmental toxins, the functional alterations progress to early 
structural changes. once these set in, further progression to irreversible 
damage and end stage disease is apparently determined by yet unknown 
factors independent of hyperglycemia could be genetic. 
VASCULAR CHANGES IN DIABETES: 
To ensure adequate nutrition to all tissues, blood vessels must 
possess inherent mechanisms to regulate the flow and contractility, 
permeability, coagulation and regeneration following injury, depending on 
the needs of each tissue. 
  
  
Diabetes mellitus affects all these processes leading to damage of 
target tissues.(16) 
Reduced contractility - altered blood flow 
Thickened basement membrane - altered permeability 
Factor Vii , vWF, PGI - coagulability 
Cellular proliferation - neovascularisation 
 
MACROVASCULAR DISEASE IN DIABETES : 
 
Unlike the microvascular disease which gets clicked with the onset 
of diabetes, the macrovascular disease antedates the development of 
diabetes by several years. Around 75% to 80% of all diabetic patients will 
die, many prematurely of cardiovascular (macrovascular) disease (CVD), 
particularly coronary heart disease (CHD). Diabetic foot problems 
(gangrene, large non-healing infected ulcers) are the commonest cause of 
non-traumatic lower limb amputation. In one Indian study done at Chennai, 
the prevalence of CHD was 21.4% among diabetic patients, 14.9% among 
IGT subjects and 11% among non-diabetic patients. The of PAD in the 
same population was 6.3%.  
There is a close relationship existing between pre-diabetes, diabetes 
and macrovascular (cardiovascular) disease throughout life; and the 
substantial body of evidence supports the concept that increased risk of 
morbidity and mortality due to CVD is associated with abnormalities in 
glucose metabolism across the entire continum of glucose tolerance 
ranging from normal to clinical diabetes.(14,28) 
 
AETIOPATHOGENESIS: 
 
The central mechanism in macrovascular disease is the process of 
atherosclerosis which leads to narrowing of the arteries throughout the 
body. Atherosclerosis is a progressive disease of the arterial wall involving 
the components of inflammation, vascular lipid deposition and 
remodelling, fibrosis, and thrombosis. Diabetes is a major independent risk 
factor for CHD resulting from accelerated atherosclerosis of the coronary 
arteries occurring at a much earlier age and advancing more rapidly to 
clinical cardiovascular events in persons with diabetes than in those 
without it.   
              Multivariate analyses of a number of large prospective studies 
with a followup of 12 to 20 years have shown that diabetes is associated 
with 2- to 5-fold increase in CHD and premature cardiovascular-related 
deaths in both type 1 and type 2 diabetes. Atherosclerosis in diabetes is 
typically more diffuse, heterogeneous and extensive, occurring earlier and 
faster and more often associated with high-risk, unstable and vulnerable 
plaque with a large lipid core covered by thin fibrous cap which can easily 
rupture and result in acute coronary syndrome and death than in those 
without the diabetes. Diabetes, therefore, has definite accelerating impact 
on the pathogenesis of atherosclerosis which, in fact, is not qualitatively 
different from that occurring in non-diabetic individuals. 
CLINICAL MANIFESTATIONS OF MACROVASCULAR 
DISEASE 
 
Cardiovascular Disease : 
Cardiovascular syndromes in patients with diabetes present in 
similar ways to those in non-diabetic population, although many patients 
are younger, outcomes are worse, and ischaemic events are more likely to 
be ‘painless’ (or rather silent) due to associated cardiac autonomic 
neuropathy. A cluster of cardiovascular risk factors clinically relevant are 
associated with diabetes, pre-diabetes, and IR and have to be looked into 
while evaluating the diabetic patients.  
 
These are: 1. Abdominal obesity with increased waist circumference 
(> 90 cm in men and >80 cm in women) acanthosis nigricans, ‘hump’-like 
fatty bulge nape of the neck  
 
2. Hypertension (>140/90 mmHg)  
3. Dyslipidaemia Increased triglycerides Decreased HDL cholesterol Small 
dense atherogenic LDL particles Post-prandial lipaemia 
4. Microalbuminuria  
5. Increased levels of PAI-1 activity and fibrinogen  
 
  The clinical syndromes of myocardial ischaemia due to occlusive 
CAD are: 
1. Angina 
Angina may be relatively painless and can present atypically in long-
standing type 2 diabetic patients, particularly the older ones with 
autonomic (sensory) neuropathy. Diabetic patients are more likely to 
remain asymptomatic while showing the ECG changes during exercise 
testing or ambulatory (Holter) ECG monitoring. Such diabetic patients of 
angina show reversible ischaemia on myocardial isotope perfusion 
scanning in the absence of obvious angina. Silent myocardial ischaemia 
carries a more ominous prognosis in diabetic patients than in the non-
diabetic people. 
2. Acute coronary syndromes : 
 Unstable angina, non-ST elevation MI, and ST elevation MI 
represent a major cause of death in the diabetic population. These may also 
be painless or present with other symptoms like acute dyspnoea (left 
ventricular failure, LVF), a variety of cardiac arrhythmias often lethal, 
cardiogenic shock, or sudden death. Malaise, nausea and vomiting, profuse 
sweating or collapse are the accompanying features. Because of loss of 
normal circadian pattern of autonomic cardiovascular regulation, most 
acute ischaemic events occur during the evening and at night among 
diabetic patients.  
 
Diabetic patients who suffer an MI have a higher mortality than non-
diabetic patients both in acute phase and on long-term follow-up. Infarct 
expansion or/and extension and recurrence of infarction, acute LVF, and 
congestive heart failure (CHF) all occur more commonly in the diabetic 
population than the non-diabetic population. Serial determinations of CK-
MB and quantitative estimation of troponins are more useful in assessing 
the infarct size and recurrence. All modes of echocardiography (2-D, 
Doppler and myocardial contrast echo) are extremely useful in assessing 
the LV size and function, myocardial viability, presence of any thrombus 
in the LV or its walls and other mechanical complications like mitral 
regurgitation, ventricular septal rupture or ventricular aneurysm. A major 
cause of adverse outcomes is the five-fold higher frequency of cardiac 
failure. 
3. Heart failure: 
  Heart failure (HF) is 2 to 5 times more common in diabetic 
population than in non-diabetic population. HF can occur even in the 
absence of obvious CAD. Aetiology of HF in diabetes is complex; factors 
include the systolic and diastolic performance of the LV affected by 
diabetic cardiomyopathy (diabetic heart muscle disease), the superimposed 
deleterious consequences of hypertension and further loss of functioning 
myocardium following acute coronary artery occlusion. The contractility 
of the non-infarcted myocardium in diabetes is much reduced which adds 
further to HF. 
 
4. Cardiac dysrhythmias: 
 They are related to ischaemia, left ventricular hypertrophy or CAN 
and frequently occur in diabetic subjects following MI and may result in 
sudden death. Decreased heart rate variability and subtle changes in CV 
reflexes due to CAN in the diabetic patients result in lethal cardiac 
dysrhythmias.  
 
5. Diagnosis of ischaemic heart disease:  
  ECG, stress testing either treadmill (TMT) or pharmacologic 
(Dobutamine), ambulatory ECG (Holter) monitoring, echocardiography 
and ultimately coronary angiography should be done at appropriate times 
in the diabetic patients with IHD with or without symptoms. Coronary 
revascularisation can be very beneficial in the diabetic patients with CAD. 
(14,28) 
 
Cerebrovascular Disease 
Transient ischaemic attack and stroke are more frequent among 
diabetic patients, than in the non-diabetic patients particularly those who 
had acute coronary ischaemic event earlier. Lacunar infarcts, large infarcts 
and multi-infarct disease occur more often among the diabetic population 
than in the non-diabetic population. Haemorrhagic strokes occur less 
commonly. The prognosis of stroke is also worse in the diabetic patients. 
Hypertension often coexists and worsens the situation.  
 
Coma, convulsions and dense hemiplegias are often present. Carotid 
artery Doppler and B-Mode ultrasound imaging to measure the carotid 
intima-media thickness (IMT, abnormal if more than 1.1 mm) is an 
extremely simple and yet accurate indication of the diffuse atherosclerosis 
occurring in coronary and other arteries. The obstructive athero-plaques 
may be found in the carotid arteries by ultrasound and colour Doppler. CT 
or MRI brain and MR angiography of the brain are extremely useful in 
diagnosis as well as in prognosticating the stroke.  
  
 
 
 
Stroke-related dementia and recurrence of stroke are more frequent 
in diabetic patients. Cerebrovascular mortality rate is higher in both type 1 
and type 2 diabetic patients. 
  
Peripheral Arterial Disease 
PAD is 2 to 3 times more frequent in diabetic males and 5 to 6 times 
more common in diabetic females. Diabetes is the commonest cause of 
non-traumatic limb amputation. Smoking, hypertension and dyslipidaemia 
and associated peripheral neuropathy contribute to the increased 
prevalence of PAD in diabetic patients. Clinical presentation of ischaemic 
limb disease extends over a wide spectrum of intermittent claudication, 
critical limb ischaemia, and gangrene resulting from total peripheral artery 
occlusion. Limb pain either at rest or on walking is suggestive of occlusive 
PAD.  
 
Acute limb ischaemia characterised by pain, paraesthesia, pallor, 
pulselessness and perishingly cold limb may also occasionally occur. 
Chronic lower limb ischaemia involving popliteal and tibial arteries results 
from atherosclerosis in the diabetic individuals. The combination of 
ischaemic PAD, peripheral neuropathy, injury and infection results in 
diabetic foot disease 
  
CORONARY ARTERY DISEASE IN DIABETES: 
Coronary Artery Disease is about twice as frequent in diabetic men 
and four times as frequent in diabetic women after menopause compared 
to nondiabetics. In fact one third of all deaths occurring in diabetics after 
forty years of age have been attributed to CAD.  Coronary atherosclerosis 
in diabetic  women almost equals that of diabetic men. In contrast disease 
has distinct male predominance compared to women among nondiabetic 
subjects. It has been observed that the immunity from cardiovascular 
mortality in the premenopausal non diabetic women is seldom encountered 
in the female diabetic subjects. 
Coronary artery disease in diabetes  is characterised by greater 
prevalence of triple vessel disease. The distribution of fatty streaks, fibous 
plaques and coronary stenosis are relatively more. A correlation between 
the extent and severity of coronary atherosclerosis, with the duration of 
diabetes has not been established. The prevalance of diffuse coronary 
atherosclerosis ,as evidence by postmortem arteriography and histological 
analysis is more often seen in diabetes subjects. 
Clinically CAD in diabetic subjects is associated with prematurity 
and asymptomatic heart disease. In fact 75% of subjects sustaining acute 
myocardial infarction before 45 years of age have some form of glucose 
intolerance. 
An abnormal resting ECG has been documented  in about 40% 
normotensive, ambulant diabetic subjects. Silent myocardial infarction is 
an entity with a greater prevalence in diabetic subjects.(16) 
CAROTID INTIMA MEDIA THICKNESS 
Carotid intima-media thickness (CIMT) is a well-described 
surrogate marker for macrovascular disease,  a thickened CIMT correlates 
with the presence of macrovascular diseses by cross-sectional analysis. 
Several prospective studies have shown an association between increased 
CIMT and the incidence of macrovascular disease in the general population 
with or without prior cardiovascular disease. CIMT is significantly higher 
in diabetic patients than in nondiabetic subjects, and an increased CIMT is 
associated with angiography-evaluated coronary artery disease and 
predicts future events of macrovascular disease in type 2 diabetic subjects. 
CIMT measurements are used in clinical trials to evaluate the 
efficacy of interventions. In these trials,CIMT is used as an surrogate for 
macrovascular diseases morbidity and mortality on the premise that 
changes in CIMT reflect changes in risk of these disease.  CIMT usage is 
an advantage in a longitudinal trial as a surrogate end point to assess 
progression of atherosclerosis is the considerable reduction in duration of 
follow-up, and in sample size and it could contribute to investigating the 
cause-and-effect relationship in  atherosclerosis process.(17,18) 
“STUDY OF CAROTID ARTERY INTIMA-MEDIA THICKNESS 
BY DOPPLER ULTRASOUND-AS AN INDICATION OF 
ATHEROSCLEROSIS” 
“High resolution B-mode ultrasound is an non-invasive technique 
widely used to assess atherosclerosis in the superficial arteries. It is used to 
assess the accurate measurement of the distance between blood -intima and 
media-adventitia interfaces of the carotid wall, which is defined as carotid 
intima-media thickness (IMT)”. 
 
Several authors have suggested the carotid IMT as a marker of 
atherosclerosis in  vascular beds. 
 
 Increased carotid IMT has been associated with a number of 
atherosclerosis risk factors, with the prevalence and extent of coronary 
artery disease (CAD) and with the incidence of macrovascular disease. In 
view of these relationships, carotid IMT has been proposed as a surrogate 
endpoint to be used  as an alternative to coronary atherosclerosis.(19,21) 
 Figure 2 : Sonographic Evaluation of Carotid Arteries 
 
UltraSonography of the Carotid arteries: 
B-mode ultrasound offers advantages over angiography as it is  non-
invasive ,decreased risk and less expensive. By multiple serial 
measurements it   is  also   used to assess progression or regression of 
atherosclerosis . Because of all these advantages many investigators since 
mid1980s have used Carotid intima media thickness by B-mode 
ultrasonography as an important tool to assess atherosclerosis in various 
clinical trials.(23,24) 
 
Atherosclerosis is one of the inevitable accompaniment of ageing 
and its rate of development depends on various factors. Risk factors for 
accelerated atherosclerosis are hypertension, smoking, dyslipidemia and 
hyperglycemia. So it is necessary to identify subjects who are at early risk 
of developing accelerated atherosclerosis as several practical life style and 
pharmacological interventions for attenuating atherosclerosis development 
are available. 
 
Measurement of extra cranial carotid intima-media thickness by 
Bmode ultrasound imaging correlated with histopathological examination. 
The intima media thickness is at present the best-studied ultrasonographic 
marker for assesing atherosclerosis. A thickening of intima-media complex 
not only corresponds to local alterations but also reflects generalized 
atheroscelerosis. 
The normal intimal - medial thickness of common carotid artery as 
evaluated by B mode ultrasound imaging was  0.80 mm approximately. 
some authors have approximated the CIMT with the formula as (0.009× 
Age+ 0.116) 
.23Measurement of the intima-media thickness, which increases in 
the early stages of atherosclerosis, is used as a surrogate endpoint for 
clinical trials assessing whether lipid lowering medications might slow or 
reverse plaque formation.21 
Atherosclerosis within the carotid artery occurs most frequently in 
the common carotid artery bifurcation and proximal internal carotid artery. 
Also, the carotid siphon (portion within the cavernous sinus) is also 
vulnerable to atherosclerosis. Old age, male gender, smoking, diabetes, 
hypertension and hypercholesterolemia are risk factors for carotid artery 
disease. 
 
Figure 3 :“Carotid arteries are examined bilaterally in the areas of common 
carotid artery (1cm proximal to the dilatation of the carotid bulb), the carotid 
bifurcation (1cm proximal to the flow divider and internal carotid artery  
(1 cm distal to the flow divider) on the left and right sides” 
 
 Figure 4: Showing USG guided measurement of  
IMT in Common carotid artery 
 
Ultrasonographic scanning of the carotid arteries is  performed by 
using an  high resolution B mode ultrasound colour Doppler imaging and 
an electrical linear transducer is used.(23,24) 
                 “Scanning of  common carotid or internal carotid arteries in 
neck is performed bilaterally according to evading edge of second 
echogenic line. The first line represent the lumen intimal interface and the 
second line represents the collagen containing upper tunic adventitia. At 
each longitudinal projections three determinations of IMT are measured at 
the site of greatest thickness and at two points one cm above and one cm 
below from the site of greatest thickness. The three values are then 
averaged”. 
APPLICATION OF CAROTID ARTERY INTIMA MEDIA 
THICKNESS: 
Howard and colleagues, By Using B-mode ultrasound imaging   
examined the incidence of carotid atherosclerosis in the general population. 
The median carotid wall thickness ranged from 0.05 – 0.10 cm at all ages, 
with more than 5% of the cohort having wall thickness more than 0.20 cm. 
Cross-sectional analysis provide information that age-related increases in 
wall thickness average approximately 0.015 mm per year in females and 
0.018 mm per year in males at the carotid bifurcation, 0.010 per year in 
females and 0.014 per year in males at the internal carotid artery, and 0.010 
mm per year in both males and females at the common carotid artery. 
 
The association of CIMT with conventional risk factors of 
atherosclerosis, include not only  hyperglycaemia , fasting insulin and 
diabetes, but also body mass index, waist to hip circumference ratio, and 
physical inactivity  (30).  Abnormal glucose metabolism, abdominal 
adiposity and physical inactivity are associated positively with carotid 
IMT, in line with their believed contribution to atherogenesis. Similarly, 
the atherosclerosis risk in communities (ARIC) study showed that carotid 
wall thickness is strongly associated with  smoking , hypertension, 
atherogenesic lipids and tobacco ,(12), suggesting that the atherosclerosis 
is reflected in the IMT measurements. 
 
The prognostic value of carotid Intima-Media Thickness has been 
prospectively evaluated and in many studies, increased IMT has been 
shown to be associated with increased macrovascular complications (31-
35). In one study involving more than 4400 subjects from the 
Cardiovascular Health Study with age above 65 years and no known 
cardiovascular disease, IMT was a predictor of new cerebrovascular 
disease or acute coronary syndromes, even adjusting for traditional 
cardiovascular risk 
 
 
 
 
 
 
  
 
 
AIM OF THE STUDY: 
1.   “To compare the carotid intima media thickness in case group and 
in control population”. 
2.  “To find the association of increased carotid intima media thickness 
and CAHD/CVA/PVD”. 
3.  “To assess the usage of carotid intima media thickness as a early 
predictor of macrovascular complications in type 2 Diabetics”. 
 
  
Justification for study: 
 
“Atherosclerosis typically occurs over a period of many years, 
usually many decades. After a generally prolonged  silent period, 
atherosclerosis may become clinically manifest. Evaluation of intimal 
medial thickness is considered as surrogate marker of Atherosclerosis. B 
mode ultrasound was found to be a suitable non-invasive method to 
visualize the arterial walls and to monitor the early stages of the 
atherosclerotic process”. 
 
 
 
 
  
METHODS AND MATERIALS 
 
Study Design: Case control Study (type 2 dibetes mellitus patients 
with macrovascular complications as cases and without 
macrovascularcomplications as control group) 
 
Study population: Type 2 DM patients presenting with 
macrovascular complications admitted in the medical ward will be 
included in the study. An equal number of age, sex, BMI and comorbid 
conditions[ Systemic Hypertension] matched persons not having 
macrovascularcomplications attending OPD and in ward will be included 
in the study as control group 
 
INCLUSION CRITERIA 
1.     Patients aged  35 TO 75years with type 2 diabetes mellitus 
2.  CAHD/CVD/PVD Diagnosed through medical history, clinical 
examination and appropriate investigation including 
Electrocardiogram, EchoCardiograms, and Computer 
Tomography scan 
 
EXCLUSION CRITERIA: 
 Patient with type 1 diabetes mellitus 
 Patient with hemodynamic instability – bp<90/60 mm hg 
 Patients with renal disease and liver disease both acute and chronic 
and connective tissue disorders. 
 
 Sample Size and sampling method:  Type 2 Diabetes mellitus 
patients 50 with macrovascular complications as CASES And 50 without 
macrovascular complications as CONTROLS 
 
 
So, total of 50 cases and 50 controls  was be included in the study.  
LIMITATION OF STUDY: 
 Due to limited source and practical constraints this study is being 
carried out with a small sample size. Thus the appropriate representation 
of the population and better outcomes could be attained by increasing 
sample size. 
OBSERVATION AND ANALYSIS 
 
AGE DISTRIBUTION OF CASE AND CONTROL GROUP: 
 
Age Cases Controls 
Upto 50 yrs 10 11 
51 - 60 yrs 13 12 
Above 60 yrs 27 27 
 
Total 
 
50 
 
50 
 
 
 
 
 
 
  
 
Agerange * CC Crosstabulation 
  
CC 
Total Cases Controls 
Age 
range 
Upto 50 
yrs 
Count 10 11 21 
 % 
within 
CC 
20.0% 22.4% 21.2% 
51 - 60 
yrs 
Count 13 12 25 
 % 
within 
CC 
26.0% 24.5% 25.3% 
Above 
60 yrs 
Count 27 27 54 
 % 
within 
CC 
54.0% 54.0% 54.0% 
Total Count 50 50 100 
% 
within 
CC 
100.0% 100.0% 100.0% 
Chi Square value =0.096 
P= 0.953 
  
 
 
 
 
 So, Equal number of cases and controls are selected in different 
age group 
 
 
 
 
  
SEX DISTRIBUTION OF CASE AND CONTROL GROUP: 
 
  Frequency Percent 
 Female 27 27.0 
Male 73 73.0 
Total 100 100.0 
 
Sex =   F      
Descriptive Statisticsa 
  N Minimum Maximum Mean Std. Deviation 
Age 27 45 70 61.74 8.202 
N 27         
a. Sex = F 
      
Sex = M      
      
Descriptive Statisticsa 
  N Minimum Maximum Mean Std. Deviation 
Age 73 45 76 60.07 8.571 
 N  73         
a. Sex = M 
 
 
 
   
CC 
Total Cases Controls 
Sex F Count 13 14 27 
% 
within 
CC 
26.0% 28.0% 27.0% 
M Count 37 36 73 
% 
within 
CC 
74.0% 72.0% 73.0% 
Total Count 50 50 100 
% 
within 
CC 
100.0% 100.0% 100.0% 
 
 
Chi-Square Tests 
Chi square value = .051 
p value = 0.822 
p not statistically significant so sex distribution difference in case and 
control group 
 
 Cases Controls 
Female 13 14 
Male 37 36 
 
 
 
 So, Equal number of males and females are compared in case and 
control group 
 
 
 
 
 
 
 
 SMOKING DISTRIBUTION IN CASE AND CONTROL GROUP 
 
 
 
Cases Controls 
Yes 31 33 
No 19 17 
 
 
 
 
S0, smoking didtribution in case and control group matched equally. 
 
  
MACROVASCULAR COMPLICATION DISTRIBUTION IN 
CASE GROUP: 
  Frequency Percent 
Valid   
 
50 50.0 
ACS 25 25.0 
CVA 20 20.0 
PVD 5 5.0 
Total 100 100.0 
 
 
 
  
 
 
 
 
 
HYPERTENSION IN YEARS IN CASE AND CONTROL GROUP: 
 
 
 
 So, Hypertension in case and control group matched equally 
 
 
 
 
 
 
  
 
 
 
 
DURATION OF DIABETES IN CASE AND CONTROL GROUP: 
 
 
 
 p = 0.014 so, p is stastically significant  
 
As, Duration of diabetes is significantly more in case group than 
control group 
 
  
  
BODY MASS INDEX DISTRIBUTION IN CASE AND CONTROL 
GROUP: 
 
 
 
     p = 0. 188 (p > 0.05 ). 
 Body mass index is more in case than control group but not 
statistically significant 
 
 
 
 
 
 
  
 
FASTING BLOOD SUGAR IN CASE AND CONTROL GROUP: 
 
 
 
     P = 0.000 (< 0.01) 
 
 Fasting blood sugar is statistically significant  ( p <0.01)  in case than 
control group. So, fasting blood sugar is elevated in case than control group 
  
  
POST PRANDIAL BLOOD SUGAR IN CASE AND CONTROL 
GROUP: 
 
 
P = 0.000 
 
 Post prandial blood sugar is statistically significant (p< 0.01) in case 
than control group so, PPBS is more in case group than control group 
 
 
 
  
  
 
TOTAL CHOLESTEROL IN CASE AND CONTROL GROUP: 
 
 
     P = 0.000 
 
 Total cholesterol is statistically significant (p <0.01) in case than 
control group, so total cholesterol is more in case group than control group 
people. 
 
 
 
 
 
  
 
SERUM TRIGLYCERIDE LEVEL IN CASE AND CONTROL 
GROUP: 
 
 
      P = 0.000 
 Serum triglyceride is statistically significant ( p<0.01) incase group 
than control. So, Serum triglyceride is more in cases than controls. 
 
 
 
 
  
  
 
SERUM LDL IN CASE AND CONTROL GROUP: 
 
 
P = 0.03  
 
  Serum LDL is statistically significant (p< 0.05) in  case than control 
group. So ,Serum LDL is more in cases than controls. 
 
  
  
 
SERUM HDL IN CASE AND CONTROL GROUP: 
 
 
 
  p = 0.000 
  Serum HDL is statistically significant (p <0.01). So, serum HDL is 
significantly low in cases than controls 
 
 
  
 CAROTID INTIMA MEDIA THICKNESS IN CASE AND 
CONTROL GROUP: 
 
 
 
 
So, when 0.008 mm is considered as mean,   34 cases and only 17 
controls had CIMT more than 0.008 mm. 
 
CIMT CASES CONTROLS 
<0.008 16 33 
>0.008 34 17 
  
 
   MEAN STANDARD 
DEVIATION 
STANDARD 
ERROR 
MEAN 
CIMT Cases 50 .1226 .15471 .02188 
Controls 50 .0714 .02167 .00306 
 
 
P =0.023   (< 0.05  ) which is statistically significant 
 
      Carotid media intima thickness is significantly elevated in case 
group than control group. 
 
  
DISCUSSION AND SUMMARY 
 
This is a case control retrospective study which had a sample size of 
50 diabetic with macrovascular complication as cases and without 
macrovasvular complication as controls .This study was done to assess the 
value of carotid intima media thickness in patients those who had 
macrovascular complications in diabetes patients. 
 
In this study AGE, SEX, SMOKING, HYPERTENSION was 
equally matched in cases and controls to decrease bias of these risk factors 
influcening result of the study. 
 
          The present study emphasized that as duration of diabetes increases 
there is progression of CIMT which is statistically significant. 
 
         25 acute coronary syndrome patients , 20 cerebrovascular accident 
patients , 5 peripheral vascular disease patients with diabetes mellitus were 
included in the study and 50 diabetic without complications were included 
in the study  and carotid intima media thickness in these patients was 
measured in these patients using B mode ultrasonogram.  
  
 
 
The present study has demonstrated the role of traditional risk 
factors like total cholesterol, LDL Cholesterol and triglycerides in the 
progression of atherosclerosis found to have statistical significance in cases 
than controls. 
 
          Serum HDL was significantly low in cases than controls. 
 
          Both fasting and postprandial blood sugar was elevated in cases 
when compared with controls. 
 
          The normal intimal - medial thickness of common carotid artery as 
evaluated by B mode ultrasound imaging was  0.80 mm approximately 
 
          Out of 50 cases 34 had CIMT more than 0.008 mm which was 
considered as mean 
           Out of 50 controls only 17 had CIMT  more than 0.008 mm 
 
          On comparing carotid intima media thickness in cases and controls . 
cases had mean CIMT as 0.12 mm and controls had mean CIMT as 0.07 
mm. 
          CIMT was significantly increased in case group than control group 
and it is statistically significant p<0.05 using independent t test. 
 
Hence measurement of carotid intimal thickness using high 
resolution B mode ultrasonography which is non invasive well validated 
method is used to assess early manifestations of atherosclerosis and 
predictor of cardiovascular disease, cerebro vascular disease, peripheral 
vascular disease in asymptomatic as well as high risk patients such as 
dyslipidemia, DM, HTN and cigarette smoking. 
 
 
 
  
CONCLUSION 
 
The present study showed increased values of CIMT in Diabetic 
patients with macrovascular complication than  Diabetic patients without 
macrovascular complications. Along with this risk factors like age, HTN, 
BMI, duration of DM, may actually have a correlation with CIMT either 
directly or indirectly influencing the disease process itself and contributing 
for atherosclerosis. 
 
Ultrasound guided CIMT measurement is non invasive, 
reproducible method for detecting of early arterial structural changes 
associated with various risk factor for atherosclerosis. 
 
Hence measurement of carotid intima media thickness by ultrasound 
Doppler is reliable and helps in early medical intervention to take care of 
risk factors and life style modification and may reduce incidence of 
macrovascular complications of type 2 diabetes mellitus. 
 
 
 
 
                           PROFORMA 
 
Name    Occupation   Hospital No 
Age     Address    Op No/Ip No 
Sex     DOA 
DIABETES HISTORY 
1. Duration 
2. Treatment history - Diet/Exercise/OHA/Insulin regular/irregular 
3. Control of DM - under good control/not under control 
4. Family h/o DM 
HYPERTENSION HISTORY 
1.No. of years and Control of hypertension-under control/ not under control 
PRESENTING COMPLAINT 
1. H/o giddiness 
2. H/o syncope 
3. H/o loss of consciousness 
4. H/o polyuria 
5. H/o polydipsia 
PAST HISTORY 
 H/o angina pain/ IHD 
 H/o CVA , H/O PVD 
 any other history – Renal failure , liver failure , connective tissue 
disorder 
 
FAMILY HISTORY 
 
PERSONAL HISTORY 
 Diet 
 Physical activity 
 Smoking 
 Alcohol 
PHYSICAL EXAMINATION 
Height: cms 
Weight: Kg 
BMI: 
Pallor: Icterus: Cyanosis: 
Clubbing: Lymphadenopathy: JVP: 
Pedal Oedema: 
VITALS 
Temperature: 
  
PULSE 
 Rate : 
 Rhythm: 
 Volume: 
 Character: 
 Vessel wall thickening: 
 Radio-radial/radio-femoral delay: 
 Other peripheral pulses - 
 
Blood Pressure: 
RR: 
Carotid Artery Bruit: 
SYSTEMIC EXAMINATION: 
Cardiovascular: 
Respiratory: 
PER Abdomen: 
CNS Examination: 
INVESTIGATIONS: 
1. Blood Routine 
2. FBS 
PPBS 
3. B.UREA     S.CREATININE 
4. S.LIPID PROFILE 
S. Triglyceridres: 
Total cholesterol: 
S.HDL: 
S.LDL: 
 
5. ECG 
6. Carotid artery Doppler 
 
  
PATIENT CONSENT FORM 
 
STUDY DETAIL : 
STUDY CENTRE : 
PATIENT’S NAME: 
PATIENT’S AGE : 
IDENTIFICATION NUMBER : 
 
I confirm that I have understood the purpose and procedure of the above 
study. I have the opportunity to ask questions and all my questions and 
doubts have been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal rights 
being affected. 
I understand that the sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will 
not need my permission to look at my health records, both in respect of the 
current study and any further research that may be conducted in relation to 
it, even if I withdraw from the study I agree to this access. However I 
understand that my identity would not be revealed in any information 
released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from this study. 
I hereby consent to participate in this study. 
I hereby give permission to undergo complete clinical examination 
and diagnostic tests including haematological, biochemical, 
radiological tests. 
Signature/thumb impression: 
Patient’s name and address:                                              
Place:                                  Date: 
Signature of the investigator: 
Name of the investigator:                                                  
Place:                              Date: 
 
LIST OF ABBREVATIONS USED 
 
DM  -  Diabetes mellitus 
HTN  -  Hypertension 
CIMT  -  Carotid intima media thickness 
TC  -  Total cholesterol 
TG  -            Triglyceride 
LDL  -  Low density lipoprotein 
VLDL  -  Very low density lipoprotein 
BMI  -  Body mass index 
ARIC  -  Atherosclerosis risk in communities 
TIA  -  Transient ischemic attack 
FBS  -  Fasting blood sugar 
PPBS  -  Post prandial blood sugar 
HDL  -  High density lipoprotein 
SBP  -  Systolic blood pressure 
Y -  yes 
HbA1C  -  Glycosylated hemoglobin 
CAD  -  Coronary artery disease 
PVD  -  Peripheral vascular disease 
CVS  -  Cardio vascular system 
CNS  -  Central nervous system 
ACS -  Acute coronary syndrome 
CCA  -  Common Carotid Artery 
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1 Rajendran 65 M CVA 7 4  25 182 300 230 200 124 37 0.09 
2 Sarada 70 F CVA 12 -  29 170 286 188 244 102 31 0.12 
3 Ramakrishna 45 M ACS 5 6  18.6 146 260 240 210 144 40 0.14 
4 Kamala 70 F ACS 9 2  24 168 380 201 172 137 30 0.12 
5 Dharmalingam 65 M CVA 7 1 Y 26 172 356 194 211 118 34 0.06 
6 Shankaran 70 M ACS 5 - Y 27 124 292 236 356 137 28 0.06 
7 Chandra 70 F ACS 6 -  25 132 313 202 176 136 31 0.09 
8 Ananth 
60 M ACS 11 8 Y 24 162 310 212 203 137 34 0.13 
9 Andal 
65 F ACS 5 10  31.5 177 289 196 155 117 38 1.17 
10 Ramaiya 65 M PVD 7 4 Y 30 150 266 233 200 152 41 0.14 
11 Rangasamy 
70 M ACS 8 8 Y 29 188 319 183 154 115 37 0.07 
12 Venkateshan 
65 M CVA 9 15 Y 28.5 134 366 248 273 162 31 0.17 
13 Shivalingam 50 M CVA 14 - Y 24.6 232 388 201 244 133 38 0.08 
14 Janarthanan 54 M CVA 11 3  30.5 210 462 217 310 125 30 0.12 
15 Gangatharan 58 M ACS 8 5  32.0 168 298 197 262 107 38 0.05 
16 Narasaiya 55 M ACS 6 1 Y 26 136 273 176 180 96 44 0.08 
17 Babu 50 M PVD 5 - Y 28 171 304 202 212 120 40 0.09 
18 Lingeshwaran 70 M ACS 7 4  25 223 355 232 296 141 32 0.12 
19 Munusamy 65 M CVA 4 6 Y 24 122 256 158 144 86 43 0.12 
20 Kandasamy 65 M CVA 10 1  29 202 363 206 219 125 37 0.07 
21 Balaraman 
52 M ACS 9 - Y 28 132 312 211 198 132 39 0.08 
22 Raju 56 M CVA 7 1 Y 23.5 196 288 192 241 108 36 0.14 
23 Narasimma 
45 M ACS 5 1  26 152 272 193 201 99 44 0.10 
24 Subramani 
45 M ACS 8 1  22 210 314 227 186 152 38 0.08 
25 Thilaga 70 F CVA 12 6  23.5 142 376 168 214 86 39 0.14 
26 Veera 70 M CVA 6 8  20 221 396 213 267 120 40 0.09 
27 Ambaram 54 M PVD 5 1  26 184 298 230 202 152 38 0.07 
28 Arumugam 
70 M ACS 9 -  18.6 142 219 181 176 106 40 0.09 
29 Chinnasamy 
60 M CVA 15 1  24 168 253 219 312 124 33 0.17 
30 Anamalai 58 M CVA 5 3 Y 26 176 366 240 190 154 28 0.08 
31 Subaiya 50 M ACS 10 2 Y 27.4 156 354 221 192 147 36 0.12 
32 Rathna 58 F ACS 10 15  25 212 306 216 176 139 42 0.14 
33 Singaram 69 M ACS 7 -  31 172 289 202 256 119 32 0.13 
34 Nagesh 45 F ACS 5 -  31.5 144 224 282 148 203 38 0.07 
35 Yashoda 55 F CVA 6 -  30 268 410 198 166 127 38 0.12 
36 Muniswaran 
70 M CVA 8 3  29 180 260 260 230 184 30 0.09 
37 Papamma 50 F ACS 7 -  28.5 136 288 152 190 74 40 0.08 
38 Muniyandi 
65 M ACS 5 - Y 27.5 160 250 220 268 130 36 0.15 
39 Kandasamy 
70 M CVA 5 - Y 30.5 126 242 183 175 108 40 0.05 
40 Ramachandra 45 M PVD 6 2 Y 32 178 311 190 261 94 44 0.07 
41 Kumaran 70 M CVA 7 -  26 235 331 230 136 140 43 0.05 
42 Parthasarathy 
57 M ACS 8 7 Y 24 200 321 204 198 122 42 0.15 
43 Nalammal 
68 F ACS 5 2  25 280 468 260 214 168 29 0.10 
44 Susheelama 
65 F CVA 7 -  24 156 301 217 228 132 39 0.07 
45 Kamala 
70 M CVA 10 10 Y 29 172 266 178 215 91 44 0.11 
46 Maha lakshm 
48 F PVD 5 -  28 146 222 170 155 86 41 0.09 
47 Rangaiah 55 M ACS 12 -  23.5 276 362 244 296 157 28 0.17 
48 Thilakan 70 M CVA 5 -  26 186 290 219 206 140 38 0.06 
49 Rajesh 62 M ACS 8 -  22 130 252 187 196 115 33 0.09 
50 Rajamma 62 F ACS 7 -  23.5 160 328 203 223 118 40 0.09 
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1 Lakshmi 70 F 5 -  18.5 126 258 196 172 123 39 0.05 
2 Alagan 70 M 7 8  19 130 321 163 134 89 47 0.06 
3 Mary 65 F 15 5  26 178 234 176 182 106 38 0.11 
4 Muthu 70 M 3 - Y 19.5 145 317 212 146 145 37 0.06 
5 
Thiyagaraja
n 
57 M 5 -  22 108 231 221 196 142 40 0.07 
6 Subaash 65 M 3 2 Y 23 118 256 169 122 103 42 0.05 
7 Robert 65 M 7  Y 32.3 130 259 210 136 140 43 0.05 
8 Saroja 65 F 6 -  33.2 88 124 183 219 106 33 0.06 
9 Jayammal 60 F 5 -  21 119 149 202 132 139 37 0.06 
10 Amalraj 50 M 9 -  26 148 198 160 114 97 40 0.06 
11 Ramayee 70 F 10 1  29 201 356 221 186 145 35 0.11 
12 Subramani 47 M 4 4  32.7 176 333 176 146 145 37 0.08 
13 Selvi 65 F 3 4  23 130 246 192 141 125 39 0.06 
14 Lakshmi 50 F 5 -  25.5 150 250 206 152 136 40 0.05 
15 Meenamma 70 F 9 5  30.8 192 336 198 210 126 36 0.12 
16 Ramu 68 M 5 5 Y 26.1 123 184 212 146 145 37 0.09 
17 Latha 65 F 2 -  24.3 96 130 173 159 102 40 0.04 
18 
Gangadhara
n 
65 M 3 5  20 107 143 152 162 82 38 0.05 
19 Nagaraj 70 M 4 6  27 187 224 186 170 112 40 0.07 
20 Kuppammal 54 F 7 15  24.5 212 346 176 152 106 40 0.09 
21 
Ramachandr
an 
65 M 15 -  27.5 188 240 177 146 104 44 0.06 
22 Ranjani 62 F 12 -  20.5 173 330 184 117 119 42 0.07 
23 Janartthan 50 M 5 2 Y 28.5 131 233 154 130 80 48 0.05 
24 Arun 58 M 5 3 Y 25.5 112 256 209 235 121 41 0.05 
25 Ramesh 60 M 8 1  23.4 107 243 173 159 102 40 0.07 
26 
Mahashwara
n 
76 M  -  25.6 124 181 142 133 68 47 0.06 
27 Noorjakan 45 F 4 -  24.5 81 167 142 176 163 40 0.05 
28 Vijaykumar 52 M 6 -  26.7 149 278 186 122 118 44 0.06 
29 Chinnaiya 68 M 7 8 Y 29.3 117 158 192 113 124 45 0.06 
30 Varadhan 70 M 13 5  28.2 163 226 210 192 133 34 0.14 
31 Babu 50 M 5 - Y 25.5 106 342 163 132 91 46 0.06 
32 Antony 55 M 7 5 Y 19 138 258 173 159 102 40 0.09 
33 Gangaiah 58 M 6 4  31 120 192 173 153 102 40 0.08 
34 Jegan 54 M 4 3  19.5 186 258 152 133 77 48 0.06 
35 Venkatesh 65 M 10 4 Y 22 252 382 180 179 111 37 0.12 
36 Ramanna 70 M 8 8 Y 23 157 259 198 170 126 38 0.08 
37 Loganadhan 50 M 5 - Y 32.3 92 146 210 172 133 43 0.06 
38 
Ramakrishn
an 
45 M 7 6  33.2 138 247 198 170 126 38 0.08 
39 Santhosh 65 M 5 - Y 21 116 200 158 190 73 47 0.06 
40 Durai 65 M 4 -  25.5 132 214 166 152 93 43 0.06 
41 Revathy 65 F 5 -  26 114 164 221 195 137 45 0.06 
42 Mohammed 50 M 4 - Y 32.7 193 350 170 135 105 38 0.07 
43 Arun 55 M 9 5 Y 25 110 246 210 222 133 36 0.11 
44 Thinnaiya 58 M 3 4  22 116 250 202 132 139 37 0.09 
45 Joseph 54 M 2 3  23 172 280 162 142 89 45 0.06 
46 Kumaran 65 M 5 4 Y 27 103 157 135 157 58 46 0.06 
47 Elumalai 70 M 7 8  26.5 148 224 202 132 139 37 0.08 
48 Ramesh 50 M 5 - Y 19 139 262 176 168 104 48 0.07 
49 Shanmugam 45 M 3 6  23 92 215 221 196 142 42 0.09 
50 Shanthi 65 F 7 -  28.5 128 236 232 146 163 40 0.07 
 
 
  
 
